Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by increased peripheral immune platelet destruction and megakaryocyte defects in the bone marrow. Although ITP was originally thought to be primarily due to antibody-mediated autoimmunity, it is now clear that T cells also play a significant role in the disease. However, the exact interplay between platelet destruction, megakaryocyte dysfunction and the elements of both humoral and cell-mediated immunity in ITP remains incompletely defined. While most studies have focused on immune platelet destruction in the spleen, an additional possibility is that the antiplatelet antibodies can also destroy bone marrow megakaryocytes. To address this, we negated the effects of T cells by utilizing an in vivo passive ITP model where BALB/c mice were administered various anti-aIIb, anti-b3 or anti-GPIb antibodies or antisera and platelet counts and bone marrow megakaryocytes were enumerated.
| INTRODUCTION
Immune thrombocytopenia (ITP) is an autoimmune bleeding disease characterized by an isolated thrombocytopenia without any other haematological abnormalities except anaemia due to blood loss. 1 The pathogenesis of ITP is complex both at the level of immune system abnormalities and how the thrombocytopenia is induced in the disease. [2] [3] [4] For example, the thrombocytopenia of ITP is due to at least 2 major mechanisms, either increased peripheral platelet destruction in the spleen or reduced platelet production from the bone marrow. [4] [5] [6] [7] The mechanism of peripheral platelet destruction in ITP has been studied extensively and is thought to be primarily due to increased FcR-dependent phagocytosis of opsonized platelets by splenic macrophages. [2] [3] [4] This immune platelet destruction is associated with a vast array of peripheral and splenic B cell and T cell defects involving, for example, cytokine defects, Th1-skewness, Treg abnormalities and loss of tolerance. [2] [3] [4] Less is known, however, about the immune mechanism(s) of reduced platelet production in ITP although there are some early and recent clues. In 1915, Frank first proposed that there was a platelet production abnormality in patients with ITP. 8 Subsequently, Dameshek and Miller examined the bone marrow of patients with ITP and found increased numbers of megakaryoblasts along with elevated numbers of degenerated megakaryocytes and decreases in the number of mature megakaryocytes shedding platelets. 5 Houwerzijl et al 6 confirmed these findings by studying the fine ultrastructural characteristics of bone marrow megakaryocytes from patients with ITP using electron microscopy. Of interest, they observed apoptotic morphological abnormalities of megakaryocytes and this was confirmed by showing increased caspase-3 expression in the megakaryocytes. 6 The immune nature of the megakaryocyte abnormalities was first shown by 2 groups that both demonstrated reduced in vitro megakaryocyte growth upon addition of antiplatelet autoantibodies with various specificities, for example anti-aIIb, vs anti-b3. More recently, it has become evident from murine models that cytotoxic T cells may also play a significant role in megakaryocyte destruction in ITP; 9,10 however, the exact interplay between megakaryocyte dysfunction, platelet production and the elements of both humoral and cell-mediated immune systems remains incompletely understood. Figure S1 . Mouseanti-mouse CD61 sera (anti-b3) was obtained from b3 KO mice immunized with syngeneic CD61+ platelets as previously described. 9 PBS, normal mouse sera (NMS) and a monoclonal IgG isotype control antibody were used as sham controls. To passively induce ITP, all sera and antibodies were administered by an intraperitoneal (ip) injection and there optimal doses were determined by previous titration experiments. For intravenous immunoglobulin (IVIg) treatment of ITP, IVIg was administered ip at 2 g/kg, 5 minutes prior to the antibody injection. Anti-b3, mouse-anti-mouse b3 serum; RAMS, rabbit-anti-mouse platelet serum.
| Platelet counts
Mice were bled via the saphenous vein into PBS with 10% CPDA 24 hours after antibody/sera injection, and platelet counts were measured using a Beckman Coulter Counter-LH750 haematology analyser as previously described. 
| Bone marrow histology and megakaryocyte count
Mice were sacrificed 24 hours after antibody/sera injection, and femurs were collected and dissected of muscle tissue. The epiphyses were cut off, and the bone shafts were placed in fixative (B+ fixative; BBC Biochemicals) for 12 hours. The bones were further decalcified with 10% nitric acid for 2 hours and then processed and embedded in paraffin. Sections were stained with haematoxylin and eosin (H&E). All pictures were taken using the CellSens Standard software under a 409 objective lens (Olympus BX50) with the numerical aperture of objective lens set at 0.75. Images of 10 random fields (450 lm 9 320 lm/ field) throughout each slide were taken from every mouse. 10 The images were then randomized and blindly assigned to 3 individuals who were trained in megakaryocyte enumeration. The megakaryocyte count of each mouse was calculated as the mean value of 30 fields.
| Statistical analysis
Statistical analyses were performed using Prism software (version 6.0; GraphPad Software, San Diego, CA). Data are presented as mean AE standard deviation (SD). One-way ANOVA with Tukey's post hoc test and t test was used for data analysis, and P values of <.05 were regarded as significant.
| RESULTS

| The severity of thrombocytopenia varies depending on the antiplatelet antibody used
Compared with the PBS/NMS/isotype control sham injection, the anti-b3 sera and RAMS induced the most significant (P < .0001) thrombocytopenia in recipient mice by 24 hours post-injection ( Figure 1A ). The mAb also induced significant thrombocytopenia in the BALB/c recipient mice; however, the severity of thrombocytopenia varied depending on the antibody used ( Figure 1A) . Although all the NIT-B, NIT-E, NIT-G and NIT-H1 antibodies were of the same host and specificity (anti-GPIb), the thrombocytopenia induced by NIT-E was more moderate compared with RAMS or MWReg30 and NIT-G, NIT-B nor NIT-H1 ( Figure 1A) . Treatment of the recipient mice with 2 g/kg IVIg variably antibody/sera injected, the platelet counts after IVIg (2 g/kg) treatment are also shown (grey circles). Comparisons among all groups were analysed using one-way ANOVA with a Tukey's post hoc test (*P < .05, ****P < .0001). The * are P value comparisons between the antibodymediated platelet counts and their corresponding IVIg treatments whereas **** indicate P values when compared to control. The hatched horizontal line is 2 SD from the mean of the PBS control alleviated the thrombocytopenia in the mice except for the mice treated with monoclonal antibody, NIT-E ( Figure 1B ).
| Antiplatelet antibodies have differential effects on bone marrow megakaryocytes
Examination of the megakaryocyte counts in the bone marrow also showed variable effects by injection of the antiplatelet reagents. For example, although all the sera and antibodies induced thrombocytopenia, only the anti-b3 sera and mAb MWReg30 significantly increased the number of megakaryocytes as compared with controls ( Figure 2A ). In addition, these 2 antiplatelet reagents caused significant morphological abnormalities consisting of pyknotic nuclei and cytoplasmic blebbing (Figure 3) . In contrast, megakaryocyte counts in the 2C9.G2, NIT-G-and NIT-H1-treated groups were significantly lower than in antib3 group (Figure 2A ). Of interest, megakaryocyte counts were only modified by IVIg treatment in the MWReg30 group ( Figure 2B ).
| DISCUSSION
In this study, the effects of different antiplatelet antibodies on platelet and megakaryocyte counts were examined independently of T cells in a murine passive ITP model. While all the antiplatelet sera and mAbs induced variable degrees of significant thrombocytopenia in BALB/c mice within 24 hours of administration, only 2 antiplatelet reagents caused significant elevations and abnormal morphology in bone marrow megakaryocytes. These results suggest that antibodies of different antiplatelet specificity have different biological effects on megakaryocytes in vivo. In addition, while IVIg administration successfully alleviated the thrombocytopenia induced by the antiplatelet antibodies, its effect on megakaryocyte number and morphology was limited.
Megakaryocytes are a specialized cell population in the bone marrow that develop from CD34 + CD41 + progenitor cells to become lineage restricted and express CD61 (integrin b3, GPIIIa) and CD41 (integrin aIIb, or GPIIb).
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Their development can be divided into 3 different stages: megakaryoblasts, promegakaryocytes and mature megakaryocytes, 5, 13, 14 and their maturation and proliferation are critically dependent on the megakaryocyte growth factor thrombopoietin (TPO). 15 Mature megakaryocytes eventually release pro-platelets into the bloodstream which eventually become circulating platelets. [16] [17] [18] [19] In ITP, although antibody-mediated peripheral destruction of platelets was the earliest manifestation discovered, 7, [20] [21] [22] [23] [24] it is now known that platelet production from megakaryocytes in ITP is defective and this contributes to the thrombocytopenia in patients, but little is known of how reduced platelet production in the bone marrow is mediated. effects on megakaryocytes. Although the autoreactive antibodies and T cells could target both platelets and megakaryocytes, binding to platelets leads to enhanced platelet clearance whereas binding to megakaryocytes does not necessarily induce cell clearance but rather changes in apoptosis, maturation defects and decreased pro-platelet formation. The total number of megakaryocytes in the bone marrow seems to be normal or increased in patients with ITP. [4] [5] [6] In 2003, Chang et al 25 showed that plasma from ITP patients as well as purified antiplatelet monoclonal antibodies could inhibit megakaryocyte differentiation in vitro. McMillan et al 26 further showed that antiplatelet antibodies from patients with ITP could also inhibit the maturation of megakaryocytes in a variable manner in vitro. Subsequently, Balduini showed that anti-GPIba but not anti-aIIbb3 antibodies inhibited pro-platelet formation by megakaryocytes in vitro, suggesting an additional mechanism that contributes to the thrombocytopenia in ITP. 27 Animal models of ITP have also recently shown that CD8 + T cells can significantly affect megakaryocytes. For example, Li et al 28 showed that CD8 + T cells from patients with ITP could increase the number of megakaryocytes but decrease platelet production. Furthermore, Chow et al 9 have shown that CD8+ T cell-mediated ITP is associated with significant in vivo megakaryocyte defects that were resistant to IVIg therapy. Despite these observations, to our knowledge, the in vivo effects of antiplatelet antibodies, independently of CD8 + T cells, on the megakaryocytes in ITP have not been studied. Animal models provide a valuable tool to facilitate our understanding of the pathogenesis of ITP. 29 Passive ITP is the most commonly used mouse ITP model and is generated by injecting antiplatelet sera or mAb into mice. 29 For example, in 1981, RAMS was used to induce thrombocytopenia, for the study of changes in small acetylcholinesterase-positive cells in the bone marrow, which were recognized as megakaryocyte progenitor cells. 30 The earliest antiplatelet monoclonal antibodies were probably developed in 1981 by McMichael and Newman independently 31, 32 and in 1992, one of the first antimurine platelet mAbs, MWReg30 was developed by Burstein et al 33 and
has been widely used to induce passive ITP. In the current study, all the antiplatelet sera and mAbs induced significant thrombocytopenia within 1 day, irrespective of being from different hosts or IgG isotypes ( Figure 1 and Table 1 ). This is consistent with our previous studies and others. 29, 34, 35 However, bone marrow megakaryocyte counts revealed significant differences among the groups of antibody-treated mice. For example, although RAMS, anti-b3 sera and MWReg30 induced comparable severity of thrombocytopenia (Figure 1 ), the megakaryocyte count was significantly higher in the anti-b3 sera or MWReg30-treated groups compared with the RAMS (Figure 2A ). This suggests that the number of megakaryocytes does not necessarily indicate actual platelet production rate and may not be proportional to platelet number in the periphery. The difference in megakaryocyte counts between the anti-b3 sera and RAMS might also be related to the differences in the antibody specificities or antibody clearance kinetics related to the Fc structure of the antibodies. The megakaryocyte counts of the MWReg 30-treated mice were the highest among all groups while the platelet counts of these mice were significantly reduced (Figures 1 and 2) . Considering the antigen specificities of the antibodies, it seems possible that the interaction between MWReg 30 and its cognate antigen CD41 could stimulate megakaryocyte progenitors to promote the production of megakaryocytes. Support for this, at least, is that the binding of MWReg30 to CD41 significantly increases platelet activation whereas other anti-GPIIbIIIa (CD41/CD61) mAb actually inhibit platelet activation. 33, 36 Alternatively, it might also be possible that the difference between MWReg30 and the other mAbs is due to an inhibitory effect of anti-GPIb (CD42) mAbs on megakaryocyte differentiation or proliferation. There is supportive evidence from the study by Balduini et al 27 showing that anti-GPIb antibody but not anti-GPIIbIIIa antibody inhibited pro-platelet formation from megakaryocytes in vitro. In addition, other host antibodies including rabbit, rat and Armenian Hamster, have been included in our current study and the clearance kinetics of xenogeneic antibodies could be different between alloantibodies and autoantibodies. To support this, a closer comparison between anti-b3 sera and other autologous antibodies-treated mice (NITs) suggests that the antigen specificity/isotype can be a contributing factor for the heterogeneity in megakaryopoiesis.
Comparisons of the 4 different anti-GPIb mAbs including NIT-B, NIT-G, NIT-G, NIT-H1 showed comparable numbers of megakaryocytes in the bone marrow, despite a trend of higher platelet counts in the NIT-E-treated group (Figure 1A) , suggesting that the number of megakaryocytes in the bone marrow may not be sensitive to increased platelet destruction and thrombocytopenia. Similarly, others have shown that the number of megakaryocytes and progenitors does not significantly change within 7 days after an antiplatelet serum injection. 37, 38 However, in these studies there was an increase in the size of megakaryocytes, which needs to be further confirmed in our mouse model. 37, 38 Overall, the different megakaryocyte counts between MWReg30 and the other mAbs and the similarities among anti-GPIb antibodies suggest that the antigen specificity of Abs may determine their effect on megakaryocytes. This may help explain the heterogeneity in megakaryocyte counts in ITP patients. 5, 6, 39 In our study, IVIg treatment successfully increased platelet counts in all groups except mice receiving the NIT-E mAb ( Figure 2B ). Of interest, there were no significant changes in the megakaryocyte counts in the IVIg-treated mice, except in the MWReg30-treated group. Our study confirms the effectiveness of IVIg therapy in the passive ITP mouse model, 29, 34, 40 but suggests that IVIg may not affect megakaryocyte counts in the bone marrow. In summary, antiplatelet antibodies, independently of T cells, are able to induce thrombocytopenia but most do not affect megakaryocyte counts or morphology within the bone marrow. Whether this is because T cells may be required to further cause megakaryocyte destruction is not known but we are currently studying this. Our data additionally suggest that while the thrombocytopenia induced by platelet antibodies is generally sensitive to IVIg treatment, in those mice where megakaryocyte number and morphology were affected, IVIg did not necessarily change the effect. 
